Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Average (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Equity Average readings, the most recent being $70.3 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 42.78% to $70.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $70.3 million, a 42.78% decrease, with the full-year FY2025 number at $102.2 million, down 35.56% from a year prior.
  • Equity Average hit $70.3 million in Q1 2026 for Barinthus Biotherapeutics, down from $79.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $254.0 million in Q2 2022 to a low of $70.3 million in Q1 2026.
  • Median Equity Average over the past 5 years was $179.5 million (2024), compared with a mean of $175.5 million.
  • Biggest five-year swings in Equity Average: soared 663.5% in 2022 and later tumbled 45.18% in 2025.
  • Barinthus Biotherapeutics' Equity Average stood at $243.7 million in 2022, then decreased by 21.49% to $191.3 million in 2023, then decreased by 24.31% to $144.8 million in 2024, then tumbled by 45.18% to $79.4 million in 2025, then decreased by 11.44% to $70.3 million in 2026.
  • The last three reported values for Equity Average were $70.3 million (Q1 2026), $79.4 million (Q4 2025), and $93.5 million (Q3 2025) per Business Quant data.